We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
-15.55%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$2.4B
AUM Growth
-$496M
(-17%)
Cap. Flow
+$93.2M
Cap. Flow
% of AUM
3.89%
Top 10 Holdings %
Top 10 Hldgs %
69.51%
Holding
38
New
3
Increased
9
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$54.7M |
| 2 |
Pacira BioSciences
PCRX
|
+$47.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$32.8M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$24.8M |
| 5 |
uniQure
QURE
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$92.7M |
| 2 |
MDCO
Medicines Co
MDCO
|
+$22.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$13.3M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$10.6M |
| 5 |
Adaptive Biotechnologies
ADPT
|
+$9.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
uniQure
QURE
$2.99B
| $14.4M | 0.6% |
+365,000
| New | +$21.1M |
|
|
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
| $13.8M | 0.58% |
2,700,000
| – | – |
|
28
Kodiak Sciences
KOD
$2.07B
| $7.19M | 0.3% |
500,000
-77,021
| -13% | -$1.01M |
|
29
Fennec Pharmaceuticals
FENC
$373M
| $5.32M | 0.22% |
1,105,999
| – | – |
|
|
TLGT
30
DELISTED
Teligent, Inc
TLGT
| $4.97M | 0.21% |
523,121
| – | – |
|
|
TPTX
31
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $3.76M | 0.16% |
+100,000
| New | +$4.35M |
|
|
ALIM
32
DELISTED
Alimera Sciences
ALIM
| $3.53M | 0.15% |
416,000
| – | – |
|
33
Rocket Pharmaceuticals
RCKT
$374M
| $3.33M | 0.14% |
285,714
| – | – |
|
|
34
Adaptive Biotechnologies
ADPT
$4.26B
| – | – |
-200,000
| Closed | -$9.66M |
|
35
Indaptus Therapeutics
INDP
$485M
| – | – |
-366
| Closed | -$3.56M |
|
36
PUT
iShares Russell 2000 ETF
IWM
$76.9B
| – | – |
-250,000
| Closed | -$110K |
|
|
37
CALL
Sarepta Therapeutics
SRPT
$2.19B
| – | – |
-250,000
| Closed | -$5.46M |
|
|
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-2,000,000
| Closed | -$92.7M |
|
Similar funds
GI
AIM
BEI
VNIM
MF
MC
GJL
LCAM
Avoro Capital Advisors's Q3 2019 Portfolio in Review
As of Q3 2019, Avoro Capital Advisors held 38 positions worth $2.4B, down 17% from $2.89B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Avoro Capital Advisors deployed $93.2M of net new capital in Q3 2019, opening 3 new positions and adding to 9 existing holdings. Its largest new stake was Karyopharm Therapeutics: 403,333 shares worth $58.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Medicines Co, an estimated $22.1M trimmed.
- Avoro Capital Advisors's largest Q3 2019 buy was Karyopharm Therapeutics: 403,333 shares worth $58.2M.
- Avoro Capital Advisors added most to Pacira BioSciences in Q3 2019, an estimated $47.9M increase.
- Avoro Capital Advisors's biggest Q3 2019 reduction was Medicines Co, cutting an estimated $22.1M.
- Avoro Capital Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $92.7M.
- Avoro Capital Advisors's ten largest holdings make up 70% of its $2.4B portfolio in Q3 2019.
- Avoro Capital Advisors opened 3 new positions and closed 5 in Q3 2019.
- Avoro Capital Advisors's portfolio value fell 17% quarter-over-quarter to $2.4B.
Based on Avoro Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.